| Title: |
Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer:12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease |
| Authors: |
Bolla, Michel; Neven, Anouk; Maingon, Philippe; Carrie, Christian; Boladeras, Ana; Andreopoulos, Demetrios; Engelen, Antoine; Sundar, Santhanam; van der Steen-Banasik, Elzbieta M.; Armstrong, John; Peignaux-Casasnovas, Karine; Boustani, Jihane; Herrera, Fernanda G.; Pieters, Bradley R.; Slot, Annerie; Bahl, Amit; Scrase, Christopher D.; Azria, David; Jansa, Jan; O'Sullivan, Joe M.; Van Den Bergh, Alphonsus C.M.; Collette, Laurence |
| Source: |
EORTC Radiation Oncology Group, Bolla, M, Neven, A, Maingon, P, Carrie, C, Boladeras, A, Andreopoulos, D, Engelen, A, Sundar, S, van der Steen-Banasik, E M, Armstrong, J, Peignaux-Casasnovas, K, Boustani, J, Herrera, F G, Pieters, B R, Slot, A, Bahl, A, Scrase, C D, Azria, D, Jansa, J, O'Sullivan, J M, Van Den Bergh, A C M & Collette, L 2021, 'Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer : 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. .... |
| Publication Year: |
2021 |
| Collection: |
University of Groningen research database |
| Description: |
PURPOSE: The European Organisation for Research and Treatment of Cancer (EORTC) trial 22991 (NCT00021450) showed that 6 months of concomitant and adjuvant androgen suppression (AS) improves event- (EFS, Phoenix) and clinical disease-free survival (DFS) of intermediate- and high-risk localized prostatic carcinoma, treated by external-beam radiotherapy (EBRT) at 70-78 Gy. We report the long-term results in intermediate-risk patients treated with 74 or 78 Gy EBRT, as per current guidelines. PATIENT AND METHODS: Of 819 patients randomly assigned between EBRT or EBRT plus AS started on day 1 of EBRT, 481 entered with intermediate risk (International Union Against Cancer TNM 1997 cT1b-c or T2a with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≤ 7 and PSA ≤ 20 ng/mL, N0M0) and had EBRT planned at 74 (342 patients, 71.1%) or 78 Gy (139 patients, 28.9%). We report the trial primary end point EFS, DFS, distant metastasis-free survival (DMFS), and overall survival (OS) by intention-to-treat stratified by EBRT dose at two-sided α = 5%. RESULTS: At a median follow-up of 12.2 years, 92 of 245 patients and 132 of 236 had EFS events in the EBRT plus AS and EBRT arm, respectively, mostly PSA relapse (48.7%) or death (45.1%). EBRT plus AS improved EFS and DFS (hazard ratio [HR] = 0.53; CI, 0.41 to 0.70; P < .001 and HR = 0.67; CI, 0.49 to 0.90; P = .008). At 10 years, DMFS was 79.3% (CI, 73.4 to 84.0) with EBRT plus AS and 72.7% (CI, 66.2 to 78.2) with EBRT (HR = 0.74; CI, 0.53 to 1.02; P = .065). With 140 deaths (EBRT plus AS: 64; EBRT: 76), 10-year OS was 80.0% (CI, 74.1 to 84.7) with EBRT plus AS and 74.3% (CI, 67.8 to 79.7) with EBRT, but not statistically significantly different (HR = 0.74; CI, 0.53 to 1.04; P = .082). CONCLUSION: Six months of concomitant and adjuvant AS statistically significantly improves EFS and DFS in intermediate-risk prostatic carcinoma, treated by irradiation at 74 or 78 Gy. The effects on OS and DMFS did not reach statistical significance. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
0732-183X; 1527-7755 |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/34310202; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/9d8fd893-c99a-49ce-b0e2-e6d8192f9a8d; info:eu-repo/semantics/altIdentifier/pissn/0732-183X; info:eu-repo/semantics/altIdentifier/eissn/1527-7755 |
| DOI: |
10.1200/JCO.21.00855 |
| Availability: |
https://hdl.handle.net/11370/9d8fd893-c99a-49ce-b0e2-e6d8192f9a8d; https://research.rug.nl/en/publications/9d8fd893-c99a-49ce-b0e2-e6d8192f9a8d; https://doi.org/10.1200/JCO.21.00855; https://pure.rug.nl/ws/files/201878724/jco.21.00855.pdf |
| Rights: |
info:eu-repo/semantics/openAccess ; https://www.rug.nl/library/open-access/article-25fa-pilot-end-user-agreement |
| Accession Number: |
edsbas.ACD44C52 |
| Database: |
BASE |